Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

What symbol and exchange does Pyxis Oncology shares trade?

Pyxis Oncology trades on the NASDAQ stock market under the symbol PYXS.

What is Pyxis Oncology stock price doing today?

As of October 30, 2026, PYXS stock price declined to $1.81 with 639,113 million shares trading.

What is Pyxis Oncology's Beta?

PYXS has a beta of 2.37, meaning it tends to be more sensitive to market movements. PYXS has a correlation of 0.03 to the broad based SPY ETF.

How much is Pyxis Oncology worth?

PYXS has a market cap of $150.97 million. This is considered a Micro Cap stock.

How much money does Pyxis Oncology make?

Last quarter Pyxis Oncology reported $0 in Revenue and -$.40 earnings per share. This fell short of revenue expectation by $-22,220 and missed earnings estimates by -$.05.

What is the highest and lowest price Pyxis Oncology traded in the last 3 year period?

In the last 3 years, PYXS traded as high as $6.85 and as low as $.83.

What are the top ETFs holding Pyxis Oncology?

The top ETF exchange traded funds that PYXS belongs to (by Net Assets): VTI, VXF, IBB, IWC, BUSM.

Is Pyxis Oncology (PYXS) a good investment?

PYXS has underperformed the market in the last year with a return of -47.1%, while the SPY ETF gained +12.3%. In the last 3 month period, PYXS fell short of the market, returning -36.9%, while SPY returned +2.1%. However, in the most recent 2 weeks PYXS has outperformed the stock market by returning +7.7%, while SPY returned -1.0%.

What are the support and resistance levels for Pyxis Oncology (PYXS)?

PYXS support price is $1.80 and resistance is $1.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PYXS shares will trade within this expected range on the day.